Not Yet RecruitingPhase 3ACTRN12605000350628

BNP in SOB

The impact of measuring brain type natriuretic peptide in patients with shortness of breath in the emergency department on management and subsequent patient mortality and morbidity.

Sponsor

Bayside Health

Enrollment

600 participants

Start Date

Aug 22, 2005

Study Type

Interventional

Conditions

Congestive cardiac failure (CCF)

Summary

To evaluate whether testing levels of BNP in patients presenting with shortness of breath has an impact on the management of these patients in the emergency department

Eligibility

Sex: Both males and femalesMin Age: 40 Yearss

Plain Language Summary

Simplified for easier understanding

This study is about bNP in SOB. It may be open to people who are at least 40 years old. Participants generally need to have presenting complaint of sob, of triage categories 1-3.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

To evaluate the role of B-type natriuretic peptide (BNP) in the management of patients presenting to the emergency department with the presenting symptom of shortness of breath (SOB). Patients randomised to the study group will have BNP levels tested. In the test group with a positive BNP result doctors will be encouraged to use a standardised approach to the optimum treatment of CCF. Blood is taken for BNP levels upon patient arrival and results will be available within one hour. The study duration is 18 months.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000350628